The importance of drug scheduling and recovery phases in determining drug activity: Improving etoposide efficacy in BCR-ABL-positive CML cells

European Journal of Cancer

Volumn 38, Issue 6, 2002, Pages 842-850

  Liu, W M ^a   Lawrence, A J ^a   Joel, S P ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

cdk1; Chronic myeloid leukaemia; Drug scheduling; G2 arrest; p21

Indexed keywords

CYCLIN DEPENDENT KINASE 1; ETOPOSIDE; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CDC2 PROTEIN KINASE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; G2 PHASE; HUMANS; IMMUNOBLOTTING; LEUKEMIA, MYELOID, CHRONIC; TUMOR CELLS, CULTURED;

EID: 0036206161     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00016-3     Document Type: Article

References (36)

1. Schedule dependency of anti-leukaemic activity of the podophyllotoxin-derivative VP-16-213 (NSC 141540) in L1210 leukaemia
2. In vitro cytotoxicity of VP-16 on primary tumour and metastasis of Lewis lung carcinoma
3. A randomised trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer
4. Concentration-dependent differences in the mechanisms by which caffeine potentiates etoposide cytotoxicity in HeLa cells
5. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukaemic cells to topoisomerase I and II inhibitors
6. Chronic myelocytic leukaemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage
7. Human chronic myelogenous leukaemia cell line with positive Philadelphia chromosome
8. A new leukaemia cell line with Philadelphia chromosome characterised as basophil precursors
9. Induction of apoptosis (programmed cell death) in human leukaemic HL-60 cells by inhibition of RNA or protein synthesis
10. BCR-ABL maintains resistance of chronic myelogenous leukaemia cells to apoptotic cell death
11. A minute chromosome in human chronic granulocytic leukaemia
12. A new consistent chromosomal abnormality in chronic granulocytic leukaemia identified by quinacrine fluorescence and Giemsa staining
13. Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr/abl fusion proteins
14. Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents
15. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents
16. Cell biology: The cell cycle as a cdc2 cycle
17. Universal control mechanism regulating onset of M-phase
18. Creative blocks: Cell cycle checkpoints and feedback controls
19. Activation of the various cyclin/cdc 2 protein kinases
20. Cdc2 regulatory factors
21. WAF1, a potential mediator of p53 tumour suppression
22. p21 is a universal inhibitor of cyclin dependent kinases
23. Changes in cyclins and cyclin dependent kinases induced by DNA damaging agents in human ovarian cancer cell lines expressing mutated or wild type p53
24. Evidence for different mechanisms of growth inhibition of T-cell lymphoma by phorbal esters and concanavalin A
25. Instability of the anticancer agent etoposide under in vitro culture conditions
26. Assays of cell viability: Discrimination of cells dying by apoptosis
27. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
28. Activation of c-myc expression by c-abl is independent of both the DNA binding function of c-abl and the c-myc EP site
29. Comparison of caspase activation and sub-cellular localisation in HL-60 and K562 cells undergoing etoposide-induced apoptosis
30. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis
31. Expression of wild-type p53 increases etoposide cytotoxicity in M1 myeloid leukaemia cells by facilitated G2 to M transition: Implications for gene therapy
32. Identification of p53 as a sequence-specific DNA-binding protein
33. waf1/cip1 expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis
34. waf1/cip1 in pancreatic cancer
35. The mechanisms of DNA topoisomerases